The effect of adsorbent-antioxidant vaginal gel on high-risk HPV clearance
- 11 November 2022
- journal article
- Published by Peertechz Publications Private Limited in Journal of Gynecological Research and Obstetrics
- Vol. 8 (3), 048-053
- https://doi.org/10.17352/jgro.000117
Abstract
Background: The purpose of this study is to investigate the effect of an adsorbent-antioxidant vaginal gel, which contains micronized silicon dioxide and antioxidant deflamin, on high-risk human papillomavirus (hr-HPV) clearance within the follow-up periods specified in the guidelines. Methods: In the study, the data of 52 patients infected with hr-HPV using vaginal gel for 3 months and 115 patients who were not using vaginal gel were analyzed retrospectively. Demographic characteristics, Liquid-Based Cytology (LBC) at the time of presentation, colposcopy findings, and cervical biopsy results of both groups were investigated. After the LBC and hr-HPV results were evaluated at the end of the control period, both groups were compared in terms of hr-HPV clearance. The level of statistical significance was taken as 0.05 in all tests. Results: The two groups had similar demographic data, cytological findings, colposcopy findings, and cervical biopsy results (p > 0.05). During similar follow-up periods (13.6 ± 3.2 vs. 14.1 ± 3.4 months; p > 0.05), there was no significant difference in terms of hr-HPV clearance (46.2% vs. 51.3%; p > 0.05). Furthermore, the initial and follow-up cytology results of the patients were similar (p > 0.05). Conclusions: A significant effect of the absorbent antioxidant vaginal gel on hr-HPV clearance at approximately 1-year follow-up could not be demonstrated.Background: The purpose of this study is to investigate the effect of an adsorbent-antioxidant vaginal gel, which contains micronized silicon dioxide and antioxidant deflamin, on high-risk human papillomavirus (hr-HPV) clearance within the follow-up periods specified in the guidelines. Methods: In the study, the data of 52 patients infected with hr-HPV using vaginal gel for 3 months and 115 patients who were not using vaginal gel were analyzed retrospectively. Demographic characteristics, Liquid-Based Cytology (LBC) at the time of presentation, colposcopy findings, and cervical biopsy results of both groups were investigated. After the LBC and hr-HPV results were evaluated at the end of the control period, both groups were compared in terms of hr-HPV clearance. The level of statistical significance was taken as 0.05 in all tests. Results: The two groups had similar demographic data, cytological findings, colposcopy findings, and cervical biopsy results (p > 0.05). During similar follow-up periods (13.6 ± 3.2 vs. 14.1 ± 3.4 months; p > 0.05), there was no significant difference in terms of hr-HPV clearance (46.2% vs. 51.3%; p > 0.05). Furthermore, the initial and follow-up cytology results of the patients were similar (p > 0.05). Conclusions: A significant effect of the absorbent antioxidant vaginal gel on hr-HPV clearance at approximately 1-year follow-up could not be demonstrated.Keywords
This publication has 23 references indexed in Scilit:
- Pregnancy outcome following loop electrosurgical excision procedure (LEEP) a systematic review and meta-analysisArchiv für Gynäkologie, 2013
- Comparison of the vaginal microbiota diversity of women with and without human papillomavirus infection: a cross-sectional studyBMC Infectious Diseases, 2013
- Human Papillomavirus DetectionAdvances in Anatomic Pathology, 2013
- American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical CancerAmerican Journal of Clinical Pathology, 2012
- Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial dataBMJ, 2012
- Factors associated with psychological distress following colposcopy among women with low‐grade abnormal cervical cytology: a prospective study within the Trial Of Management of Borderline and Other Low‐grade Abnormal smears (TOMBOLA)Psycho‐Oncology, 2011
- A pilot study to investigate the treatment of cervical human papillomavirus infection with zinc-citrate compound (CIZAR®)Gynecologic Oncology, 2011
- Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young womenThe Lancet, 2009
- Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical LesionsThe New England Journal of Medicine, 2007
- Epidemiology of Acquisition and Clearance of Cervical Human Papillomavirus Infection in Women from a High‐Risk Area for Cervical CancerThe Journal of Infectious Diseases, 1999